Allos Therapeutics, Inc. ALTH today announced that it continues to
work with AMAG Pharmaceuticals, Inc. towards the completion of their merger,
pending stockholder approval and satisfaction of the other conditions to
closing described in Allos' definitive proxy statement filed with the SEC on
September 15, 2011. On October 7, 2011, the publicly traded pharmaceutical
company that had previously submitted a proposal to acquire Allos for $2.20
per share in cash and stock delivered a letter to Allos withdrawing its
revised proposal to acquire Allos
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in